A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer

Trial Profile

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

At a glance

  • Drugs ABBV 075 (Primary)
  • Indications Acute myeloid leukaemia; Breast cancer; Cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 15 Dec 2016 Planned number of patients changed from 100 to 150.
    • 08 Aug 2016 Planned number of patients changed from 78 to 100.
    • 08 Aug 2016 Planned End Date changed from 1 Oct 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top